Archive
A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Vinay Prasad, controversial FDA leader, to again depart agency
Vinay Prasad, controversial FDA leader, to again depart agency
Servier to build cancer drug pipeline with $2.5B purchase of Day One
Servier to build cancer drug pipeline with $2.5B purchase of Day One
Roche, Zealand shares fall on ‘undifferentiated’ obesity drug results
Roche, Zealand shares fall on ‘undifferentiated’ obesity drug results
FDA issues speedy approval to J&J’s Tecvayli-Darzalex combo
FDA issues speedy approval to J&J’s Tecvayli-Darzalex combo
Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs
Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs
Lilly targets employers in new bid to broaden access to obesity drugs
Lilly targets employers in new bid to broaden access to obesity drugs
PepGen muscular dystrophy drug gets ‘surprise’ hold from FDA
PepGen muscular dystrophy drug gets ‘surprise’ hold from FDA
A startup making drugs for blood disorders banks $160M
A startup making drugs for blood disorders banks $160M
Moderna to pay up to $2.25B to end mRNA vaccine patent fight
Moderna to pay up to $2.25B to end mRNA vaccine patent fight
Blackstone puts $400M into Teva, Sanofi gut disease drug
Blackstone puts $400M into Teva, Sanofi gut disease drug
Prime to test FDA flexibility with 2-patient gene editing submission
Prime to test FDA flexibility with 2-patient gene editing submission
FDA again targets GLP-1 compounders; Intellia to restart heart disease trial
FDA again targets GLP-1 compounders; Intellia to restart heart disease trial
Kyowa Kirin abandons touted eczema drug following safety review
Kyowa Kirin abandons touted eczema drug following safety review
Pierre Fabre seeks to revive US approval chances for spurned cell therapy
Pierre Fabre seeks to revive US approval chances for spurned cell therapy
Ascendis wins FDA approval of dwarfism drug
Ascendis wins FDA approval of dwarfism drug
UniQure says FDA wants another study of Huntington’s gene therapy
UniQure says FDA wants another study of Huntington’s gene therapy
Roche pill succeeds in another MS study, but approval questions linger
Roche pill succeeds in another MS study, but approval questions linger
Candid, in a reverse merger with RallyBio, to go public
Candid, in a reverse merger with RallyBio, to go public
Directory ribbon
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page Thermo Fisher Core Tools & Instruments
Track Danaher Core Tools & Instruments
Track Agilent Core Tools & Instruments
Track Merck KGaA Core Tools & Instruments
Track Illumina Core Tools & Instruments
Track Waters Core Tools & Instruments
Track Bruker Core Tools & Instruments
Track Sartorius Core Tools & Instruments
Track Mettler Toledo Core Tools & Instruments
Track PerkinElmer (Revvity) Core Tools & Instruments
Track Bio-Rad Core Tools & Instruments
Track Carl Zeiss Core Tools & Instruments
Track Leica Microsystems Core Tools & Instruments
Track Nikon Core Tools & Instruments
Track Eppendorf Core Tools & Instruments
Track Corning Core Tools & Instruments
Track BD (Becton Dickinson) Core Tools & Instruments
Track Beckman Coulter Core Tools & Instruments
Track